US 12,351,599 B2
Antiviral application of nucleoside analog or combination formulation containing nucleoside analog
Yuanchao Xie, Shanghai (CN); Gengfu Xiao, Wuhan (CN); Yang He, Shanghai (CN); Leike Zhang, Wuhan (CN); Haji Akber Aisa, Xinjiang (CN); Hualiang Jiang, Shanghai (CN); and Jingshan Shen, Shanghai (CN)
Assigned to Shanghai Institute of Materia Medica, Chines Academy of Sciences, Shanghai (CN); Wuhan Institute of Virology, Chinese Academy of Science, Hubei (CN); Xinjiang Technical Institute of Physics and Chimestry, Chinese Academy of Sciences, Xinjiang (CN); and Vigonvita Life Sciences Co., Ltd., Jiangsu (CN)
Filed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai (CN); Wuhan Institute of Virology, Chinese Academy of Science, Wuhan (CN); Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Science, Urumqi (CN); and Vigonvita Life Sciences Co., Ltd., Suzhou (CN)
Filed on Nov. 27, 2023, as Appl. No. 18/519,408.
Application 18/519,408 is a continuation of application No. 17/996,430, granted, now 11,919,923, previously published as PCT/CN2021/087928, filed on Apr. 16, 2021.
Claims priority of application No. 202010313870.X (CN), filed on Apr. 20, 2020; application No. 202010568329.3 (CN), filed on Jun. 19, 2020; and application No. 202011035065.1 (CN), filed on Sep. 27, 2020.
Prior Publication US 2024/0140975 A1, May 2, 2024
Int. Cl. C07H 7/06 (2006.01); A61P 31/14 (2006.01); A61P 31/16 (2006.01)
CPC C07H 7/06 (2013.01) [A61P 31/14 (2018.01); A61P 31/16 (2018.01); C07B 2200/05 (2013.01)] 19 Claims
 
1. A compound of formula (I), or a pharmaceutically acceptable salt thereof or a crystalline hydrate thereof or a solvate thereof:

OG Complex Work Unit Chemistry
wherein,
R1 is cyano;
R2 is OR3;
one of R3 in formula (I), the R3 in the definition of R2, and R5 is selected from the group consisting of —C(O)—C3-6cycloalkyl, C1-20alkanoyl, and aminoC1-20alkanoyl; and the rest of the R3 in formula (I), the R3 in the definition of R2, and R5 are each independently selected from the group consisting of hydrogen, —C(O)—C3-6cycloalkyl, C1-20alkanoyl, and aminoC1-20alkanoyl;
R4 is hydrogen, deuterium, and halogen;
R6 is amino;
R7 is hydrogen;
R8 is selected from the group consisting of hydrogen, deuterium, and halogen; and
X is —CH2—, or —CD2-.